Senate Bill 3 permits regulators to license up to 25 marijuana cultivators and processors, and up to 150 dispensary locations to provide cannabis products to qualified patients who possess a recommendation from select physicians. Qualifying conditions eligible to receive cannabis therapy are: cancer; HIV; AIDS; ALS (Lou Gehrig’s disease); Parkinson’s disease; multiple sclerosis; damage to the nervous tissue of the spinal cord with objective neurological indication of intractable spasticity; epilepsy: inflammatory bowel disease; neuropathies; Huntington’s disease; Crohn’s disease; post-traumatic stress disorder; intractable seizures; glaucoma; sickle cell anemia; autism; neuropathic pain; or severe chronic or intractable pain that is untreatable, and/or any terminal illness. Physicians will first need to complete a specialized training curriculum before they can recommend cannabis therapy.
The measure does not permit for the inhalation of herbal cannabis products. Rather, it limits the dispensing of medical cannabis formulations to oils, pills, tinctures, liquids, and topical ointments. To date, only two other states – Minnesota and New York – impose similar restrictions regarding patients’ use of herbal cannabis.
Pennsylvania is the 24th state to permit the use of physician-recommended cannabis and/or cannabis-formulated products. The state’s Medical Marijuana Program is expected to take between 18 and 24 months before becoming operational.
For more information, please contact Danielle Keane, NORML Political Director, at (202) 483-5500 or visit: http://www.phillynorml.org.